Stockscreener 앱 받기
34.83
0.51%
-0.18
시장 영업 전:
35.10
0.27
+0.78%
전일 마감가:
$35.01
열려 있는:
$34.78
하루 거래량:
1.45M
Relative Volume:
0.76
시가총액:
$3.12B
수익:
$333.87M
순이익/손실:
$-169.00M
주가수익비율:
-17.07
EPS:
-2.04
순현금흐름:
$-157.30M
1주 성능:
-0.49%
1개월 성능:
-4.50%
6개월 성능:
+133.13%
1년 성능:
+94.47%
1일 변동 폭
$33.96
$35.13
1주일 범위
$33.84
$35.97
52주 변동 폭
$12.91
$37.50
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
34.83 | 3.13B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Squarepoint Ops LLC Grows Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Frazier Life Sciences Management L.P. Makes New Investment in Travere Therapeutics, Inc. $TVTX - MarketBeat
Birchview Capital LP Trims Stake in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 11, 2025 - BioSpace
Trading Systems Reacting to (TVTX) Volatility - news.stocktradersdaily.com
Federated Hermes Inc. Sells 145,110 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ: TVTX) issues 20,300 new-hire RSUs vesting over four years - Stock Titan
742,725 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Marshall Wace LLP - MarketBeat
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance - GlobeNewswire Inc.
Schroder Investment Management Group Decreases Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Capital Fund Management S.A. Acquires Shares of 101,406 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) CFO Christopher Cline Sells 20,000 Shares - MarketBeat
Panagora Asset Management Inc. Buys 96,062 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics CFO Sells 20,000 Shares - TradingView
Loomis Sayles & Co. L P Trims Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Is Carrying A Fair Bit Of Debt - 富途牛牛
Legal & General Group Plc Boosts Stake in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewir - The National Law Review
Travere Therapeutics (TVTX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Evercore Healthcare Conference - MarketScreener
The Insider Report: The Dip Was Bought Before the Holidays - Benzinga
Virtus Investment Advisers LLC Buys 9,699 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
F m Investments LLC Has $2.78 Million Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Is Travere Therapeutics Inc. stock a contrarian buyJuly 2025 Fed Impact & Verified Entry Point Signals - BỘ NỘI VỤ
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Thera - The National Law Review
Travere Therapeutics (NASDAQ:TVTX) Reaches New 52-Week HighHere's Why - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Travere Therapeutics (NASDAQ:TVTX) - MarketBeat
Intech Investment Management LLC Cuts Stake in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Bought by Geode Capital Management LLC - MarketBeat
SG Americas Securities LLC Purchases Shares of 31,926 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:TVTX) 2025-11-29 - Seeking Alpha
Travere Therapeutics stock hits 52-week high at 37.12 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics stock hits 52-week high at 37.12 USD - Investing.com
TVTX: HC Wainwright Reiterates Buy Rating and Maintains Price Ta - GuruFocus
HC Wainwright & Co. Reiterates Travere Therapeutics (TVTX) Buy Recommendation - Nasdaq
A Look at Travere Therapeutics’s Valuation Following FDA Updates Boosting FILSPARI’s Accessibility and Growth Prospects - Sahm
Travere Therapeutics, Inc. $TVTX Stake Lowered by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
How Travere Therapeutics Inc. stock reacts to bond yieldsWeekly Stock Recap & AI Driven Stock Movement Reports - BỘ NỘI VỤ
How Travere Therapeutics Inc. stock trades during market volatilityWeekly Stock Analysis & Safe Entry Trade Reports - moha.gov.vn
Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA (TVTX) - Seeking Alpha
Ensign Peak Advisors Inc Increases Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
How institutional buying supports Travere Therapeutics Inc. stockMarket Trend Summary & Daily Profit Maximizing Trade Tips - newser.com
Will Travere Therapeutics Inc. stock maintain dividend yieldWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Is Travere Therapeutics Inc. stock trading at a premium valuationWeekly Loss Report & AI Driven Price Predictions - newser.com
Is Travere Therapeutics Inc. stock in correction or buying zoneJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - newser.com
(TVTX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
What makes Travere Therapeutics Inc. stock attractive to growth funds2025 Top Decliners & Expert Approved Trade Ideas - newser.com
What indicators show strength in Travere Therapeutics Inc.July 2025 Price Swings & AI Powered Market Trend Analysis - newser.com
What momentum shifts mean for Travere Therapeutics Inc.2025 Technical Overview & Safe Capital Growth Stock Tips - newser.com
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):